Financing

Zai Lab posts Q3 2026 revenue of $108.2M, closes $250M private placement, advances zoci toward 2027 filings

On November 5, 2026, Zai Lab reported Q3 2026 results: total revenue of $108.2M (down from $116.1M a year earlier) and a net loss of $46.1M. The company closed a roughly $250M ADS private placement on October 27 and said that, following FDA feedback, it will pursue accelerated approval for zocilurtatug pelitecan (zoci) in 2L+ extrapulmonary neuroendocrine carcinomas. It is also advancing zoci plus atezolizumab into a global Phase 3 study in first-line extensive-stage small cell lung cancer.